NC
RNAM

nVerses Capital’s Avidity Biosciences RNAM Stock Holding History

nVerses Capital’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-3,400
Closed -$139K – 1337
2024
Q2 		$139K Buy
3,400
+700
+26% +$20.1K 0.08% 349
2024
Q1 		$68.9K Buy
+2,700
New +$42.3K 0.17% 227

Other funds holding RNAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

nVerses Capital's RNAM Position: Q3 2024 in Review

nVerses Capital sold out of Avidity Biosciences (RNAM) in Q3 2024, closing a stake of 3,400 shares — an estimated $139K sold.

nVerses Capital first reported a position in RNAM in Q1 2024 and held it in 2 quarters. The position peaked at $139K in Q2 2024. 245 funds tracked by Wall St. Rank hold RNAM as of Q3 2024.

  • nVerses Capital reported no remaining Avidity Biosciences position as of Q3 2024 after selling out during the quarter.
  • nVerses Capital sold 3,400 Avidity Biosciences shares in Q3 2024, an estimated $139K.
  • nVerses Capital first reported a position in Avidity Biosciences in Q1 2024 and held it in 2 quarters.
  • nVerses Capital's Avidity Biosciences position peaked at $139K in Q2 2024.
  • 245 funds tracked by Wall St. Rank held Avidity Biosciences as of Q3 2024.

Based on nVerses Capital's 13F filing for Q3 2024, filed 16 Oct 2024.